← Back to dossier
Patient handout

Cirrhosis (chronic, compensated + decompensated)

PRODUCTION

1. Your condition

This handout is for cirrhosis (chronic, compensated + decompensated). Your care team identified this based on: jaundice / scleral icterus.

Other reasons your team may use this plan: new or worsening ascites; variceal bleed — hematemesis / melena; hepatic encephalopathy / confusion / asterixis.

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

MedicationStarting doseHowWhenWhat it does
carvedilol6.25 mg PO daily, titrate to 12.5-25 mg BIDPOdaily/BIDBaveno VII — preferred NSBB for primary prophylaxis (better hemodynamic effect than propranolol/nadolol); reduces decompensation
propranolol20 mg PO BID, titrate to HR 55-60 or max 320 mg/dayPOBID/TIDAlternative NSBB; longer track record (Baveno VII 2022)
nadolol20 mg PO daily, titrate to HR 55-60POdailyOnce-daily NSBB option (Baveno VII 2022)

Plan: Cirrhosis complication-driven regimen — Baveno VII + AASLD 2024

3. Your action plan

Use these zones to know what to do based on how you feel.

GREENStable compensated — continue routine care
If you have:
  • Stable weight (within 1-2 kg of baseline)
  • No new confusion, sleep changes, or asterixis
  • No abdominal distension or pain
  • No bleeding, hematemesis, melena, or hematochezia
  • No yellowing of skin/eyes worse than baseline
Do this:
  • Take all liver medications as prescribed (lactulose, rifaximin, diuretics, NSBB)
  • Daily weight + sodium-restricted diet (<2 g/day)
  • No alcohol; avoid NSAIDs and herbal supplements
  • Keep all hepatology and transplant clinic appointments
  • Continue HCC surveillance imaging
YELLOWCaution — early decompensation signs, contact hepatology within 24h
If you have:
  • Weight gain >2 kg in 1 week or new abdominal swelling
  • Mild confusion, forgetfulness, or sleep reversal (HE grade 1)
  • Decreased urine output
  • Constipation or fewer than 2 BMs/day on lactulose
  • New leg swelling
  • Mild yellowing of skin/eyes worsening
  • New nausea or decreased appetite
Do this:
  • Increase lactulose to achieve 2-3 soft BMs/day
  • Strict sodium restriction <2 g/day; fluid restriction if instructed
  • Daily weight tracking — bring to clinic
  • Avoid sedatives, opioids, alcohol
  • Contact hepatology team within 24 hours
Call your provider if:
  • Weight gain >2 kg/week despite diuretics
  • Mild confusion or sleep changes
  • New leg swelling
  • Fewer BMs than usual
REDMedical alert — go to ED now
If you have:
  • Vomiting blood or coffee-ground material
  • Black tarry stool or red blood per rectum
  • Severe confusion, very sleepy, hard to wake (HE grade 3-4)
  • Severe abdominal pain or fever
  • Cannot urinate or making very little urine
  • Sudden severe shortness of breath
  • Falls or stumbling, slurred speech
Do this:
  • Call 911 / go to nearest ED immediately
  • Bring updated medication list
  • Notify hepatology team of admission
  • Family/caregiver to accompany if patient confused
Call your provider if:
  • Any red zone symptom — ED now, do not wait

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

  • Diagnostic paracentesis ANC ≥250/mm³ in cirrhotic with ascites (AASLD 2023)
  • West Haven grade 3-4 HE (somnolence, stupor, coma; airway concern) (AASLD 2023)(life-threatening)
  • Tense ascites with respiratory compromise, abdominal pain, or umbilical hernia rupture risk (ACG 2021 ascites)
  • Hematemesis / melena in cirrhotic (Baveno VII 2022)(life-threatening)
  • AKI in cirrhosis after albumin/diuretic withdrawal challenge — bland sediment, no shock, no nephrotoxin (AASLD 2023)(life-threatening)
  • Na <125 mEq/L in cirrhotic with ascites (AASLD 2023)
  • Maddrey discriminant function ≥32 in alcoholic hepatitis (ACG 2023 ALD)

5. Follow-up

Hepatology q3mo decompensated / q6mo compensated; transplant eval at MELD ≥15; addiction services for AUD; vaccinations (HAV/HBV/flu/PNA/COVID); palliative care for advanced (AASLD 2023 Biggins)

6. Sources

Guideline: AASLD 2024 Practice Guidance on Risk Stratification + Portal Hypertension/Varices + AASLD 2023 ACLF + Baveno VII (2022) + AASLD 2023 MASLD + AASLD 2023 HCC + ACG 2023 ALD

  1. pubmed.ncbi.nlm.nih.gov/35120736
  2. pubmed.ncbi.nlm.nih.gov/33942342
  3. pubmed.ncbi.nlm.nih.gov/27786365